NBP
NovaBridge Biosciences
1.40$
+0.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q1 20 | Q2 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 | 11 | 22 | 10 | 7.5 | 7.5 | 15 | 0.1 | – | 7.2 | 8.9 | 8.9 | 35 | 35 | 26 | -137 | 9.8 | 9.8 | -30 | 1.1 | 72 | 0.0 | 0.0 | 0.0 | 0.0 | 238 | 0.0 | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 23 | 23 | 14 | 14 | 27 | – | – | – | – | – | – | – | – | 0.2 | – | 0.2 | – | – | |
| 11 | 11 | 22 | 10 | 7.5 | 7.5 | 15 | -4.2 | – | 7.2 | 8.9 | 8.9 | 12 | 12 | 12 | -137 | 9.8 | 9.8 | -30 | -19 | 72 | – | – | – | – | 238 | – | -0.2 | – | – | |
| 101 | 101 | 112 | 111 | 133 | 133 | 313 | 221 | 444 | 256 | 296 | 296 | 310 | 310 | 226 | 226 | 223 | 223 | 45 | 39 | 109 | 4.5 | 6.0 | 0.8 | 3.3 | 3.2 | 56 | 7.2 | 7.1 | 73 | |
| 9.3 | 9.3 | 22 | 25 | 287 | 287 | 8.1 | 86 | 86 | 139 | 221 | 221 | 224 | 224 | 196 | 212 | 122 | 122 | 104 | 52 | 87 | 7.9 | 7.3 | 4.5 | 3.8 | 5.8 | 17 | 13 | 13 | 49 | |
| 125 | 125 | 134 | 167 | 427 | 427 | 321 | 580 | 616 | 396 | 522 | 522 | 534 | 534 | 423 | 438 | 346 | 346 | 149 | 91 | 196 | 12 | 13 | 5.3 | 7.1 | 9.0 | 73 | 20 | 20 | 123 | |
| -117 | -117 | -129 | -144 | -412 | -412 | -306 | -307 | -307 | -388 | -513 | -513 | -522 | -522 | -410 | -575 | -336 | -336 | -180 | -91 | -125 | -12 | -13 | -5.3 | -7.1 | -9.0 | -73 | -20 | -20 | -123 | |
| – | – | 1.5 | 0.2 | – | – | 0.1 | 0.1 | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -99 | -99 | -127 | -139 | -429 | -429 | -246 | -291 | -291 | -99 | -793 | -793 | -801 | -801 | 1,010 | 804 | -386 | -386 | -393 | -70 | -58 | -20 | -11 | -3.2 | -5.5 | -6.8 | -73 | -19 | -19 | -117 | |
| – | – | 1.6 | 0.1 | – | – | – | – | – | -111 | -255 | -255 | -174 | -174 | 1,533 | 1,534 | 0.0 | – | -149 | – | 6.6 | – | – | -84 | – | -384 | – | – | – | – | |
| -83 | -83 | -113 | -123 | -429 | -429 | -246 | -291 | -291 | 12 | -538 | -538 | -628 | -628 | -523 | -730 | -386 | -386 | -244 | 21 | -33 | -20 | -9.1 | -3.2 | -5.5 | -6.8 | -31 | -19 | -19 | -75 | |
| -99 | -99 | -111 | -122 | -410 | -410 | -28 | -304 | -304 | -386 | -505 | -505 | -518 | -518 | -404 | -568 | -125 | 324 | -174 | -85 | -119 | -6.4 | -13 | -5.3 | -7.1 | -8.8 | -73 | -20 | -20 | -122 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.